<DOC>
	<DOC>NCT00796601</DOC>
	<brief_summary>The hypothesis of Study A6061054 is to demonstrate superiority of efficacy of esreboxetine at 3 and 6 months compared to placebo.</brief_summary>
	<brief_title>Maintenance of Efficacy.</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<criteria>Subjects must meet the American College of Rheumatology (ACR) criteria for fibromyalgia Pain score greater than or equal to 4 on an 11point NRS FIQTotal score greater than or equal to 45 points Other severe pain that may confound assessment or self evaluation of the pain associated with fibromyalgia Any autoimmune rheumatic disorder, nonfocal rheumatic disease (other than fibromyalgia), clinically significant active infection, or untreated endocrine disorder Uncontrolled hypertension Pending Worker's Compensation; Current or recent diagnosis or episode of major depressive disorder, dysthymia and/or uncontrolled depression; Subjects to be at risk of suicide;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>double-blind placebo-controlled maintenance of efficacy</keyword>
</DOC>